Abstract: The invention provides novel compositions comprising at least two or more semifluorinated alkanes. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue, such as for use in the treatment of keratoconjunctivitis sicca (dry eye) and/or meibomian gland dysfunction and symptoms associated therewith. The invention further provides kits comprising such compositions.

Abstract: The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and retinoids.

Abstract: The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.

Abstract: The invention provides novel compositions of bioactive polypeptides and proteins with improved stability and shelf-life. The compositions are based on liquid vehicles selected from semifluorinated alkanes. These vehicles are remarkably effective in protecting polypeptides and proteins from degradation and/or aggregation. The compositions are useful for topical administration, e.g. into an eye, or by parenteral injection, e.g. via the subcutaneous or intramuscular route.

Abstract: The invention relates to the use of semi-fluorinated alkanes, in particular mixed with ethanol, as solubilising agents, permeation promoters and/or enhancers for lipophilic and/or poorly skin-permeable pharmaceutical agents that are administered via a transdermal therapeutic system (TTS), and to corresponding TTSs containing such substances.

Abstract: The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.

Abstract: The present invention is directed to certain semifluorinated compounds and to compositions comprising such compounds. The invention further provides the use of the compounds and of the compositions as medicaments for topical administration to the eye.

Abstract: The present invention is directed to compositions comprising semifluorinated compounds and their use as medicaments for topical administration to the eye.

Abstract: This disclosure provides various embodiments for providing UI services. An application-independent, reusable UI framework receives a request from a first application, to perform a first operation on a first set of data relating to presentation of the first set of data on a UI. A subset of the first set of data is received from a data provider independent of the UI framework. At least one first service is identified in response, the first service hosted by the UI framework and adapted to perform the first operation on the first set of data. The first operation is performed on the subset of the first set of data using the at least one identified first service to produce a first processed set of data adapted for presentation on a UI of the first application. The first processed set of data is sent to the first application.

Abstract: The invention provides novel compositions of antibodies based on liquid vehicles selected from semifluorinated alkanes. The use of these vehicles provides for improved stability and shelf-life of antibodies and their derivatives. The compositions are useful for topical administration or for parenteral injection.

Abstract: The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.

Abstract: The invention provides novel compositions comprising at least two or more semifluorinated alkanes. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue, such as for use in the treatment of keratoconjunctivitis sicca (dry eye) and/or meibomian gland dysfunction and symptoms associated therewith. The invention further provides kits comprising such compositions.

Abstract: The invention provides novel compositions of bioactive polypeptides and proteins with improved stability and shelf-life. The compositions are based on liquid vehicles selected from semifluorinated alkanes. These vehicles are remarkably effective in protecting polypeptides and proteins from degradation and/or aggregation. The compositions are useful for topical administration, e.g. into an eye, or by parenteral injection, e.g. via the subcutaneous or intramuscular route.

Abstract: A system and method for formatting in a database are disclosed. A request for data in a database is received from an application. The request includes one or more formatting functions to be performed on the data to display a result of the request in a graphical user interface generated by the application. The formatting functions are executed at the database to restructure the request. A query of the data in the database is then generated based on the restructured request, the query including only data to display in the graphical user interface according to the request. Then, a result of the query is returned from the database to the application for display in the graphical user interface.

Abstract: The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and retinoids.

Abstract: This disclosure provides various embodiments for providing UI services. An application-independent, reusable UI framework receives a request from a first application, to perform a first operation on a first set of data relating to presentation of the first set of data on a UI. A subset of the first set of data is received from a data provider independent of the UI framework. At least one first service is identified in response, the first service hosted by the UI framework and adapted to perform the first operation on the first set of data. The first operation is performed on the subset of the first set of data using the at least one identified first service to produce a first processed set of data adapted for presentation on a UI of the first application. The first processed set of data is sent to the first application.

Abstract: This disclosure provides various embodiments for providing UI services. An application-independent, reusable UI framework receives a request from a first application, to perform a first operation on a first set of data relating to presentation of the first set of data on a UI. A subset of the first set of data is received from a data provider independent of the UI framework. At least one first service is identified in response, the first service hosted by the UI framework and adapted to perform the first operation on the first set of data. The first operation is performed on the subset of the first set of data using the at least one identified first service to produce a first processed set of data adapted for presentation on a UI of the first application. The first processed set of data is sent to the first application.

Abstract: This disclosure provides various embodiments for providing UI services. An application-independent, reusable UI framework receives a request from a first application, to perform a first operation on a first set of data relating to presentation of the first set of data on a UI. A subset of the first set of data is received from a data provider independent of the UI framework. At least one first service is identified in response, the first service hosted by the UI framework and adapted to perform the first operation on the first set of data. The first operation is performed on the subset of the first set of data using the at least one identified first service to produce a first processed set of data adapted for presentation on a UI of the first application. The first processed set of data is sent to the first application.

Abstract: The invention relates to a topical nanoparticulate spironolactone formulation comprising nanoparticles having a mean diameter, measured by a photon correlation spectroscopy, in the range of from about 300 nm to about 900 nm. The nanoparticles are incorporated into a crystalline network system comprising a dispersion of solid crystals of polar lipids, said lipids exposing their hydrophilic side outwards and their hydrophobic side inwards towards the spironolactone nanoparticles.

Abstract: A tuning circuit for adjusting an oscillation frequency of an oscillator circuit. The tuning circuit comprises a film bulk acoustic wave resonator (FBAR) having a series resonance frequency and a parallel resonance frequency, and an inductor coupled in series or parallel with the film bulk acoustic wave resonator. The series connection of the inductor and FBAR decreases the series resonance frequency. The parallel connection of the inductor and the FBAR increases the parallel resonance frequency. The tuning circuit further comprises a varactor coupled in series or parallel with the inductor and the FBAR combination. The varactor tunes the oscillation frequency over the increased tuning range.